Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease

NCT05474560 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT05474560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05474560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease
Lead sponsor
Ain Shams University
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2022
Completion date
January 28, 2023
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia, non-alcoholic fatty liver disease